Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Breast 2Sarcoma 1Lymphoid 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 28Melanoma 9Triple Negative Breast Neoplasms 8Lung Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Neoplasms 3Mesothelioma 3Lymphoma 3Head and Neck Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2NSCLC 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2

Interventions

pembrolizumab 12Gemcitabine 9Cetuximab 7Psychiatric Rehabilitation 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Fluorouracil 6Early Intervention, Educational 6Cisplatin 6cediranib 5Leucovorin 5Carboplatin 5sargramostim 4Standard of Care 4Oxaliplatin 4Methods 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4selpercatinib 3aldesleukin 3adagrasib 3Trastuzumab 3Therapeutics 3Pemetrexed 3Nivolumab 3Irinotecan 3Fluorodeoxyglucose F18 3Bortezomib 3Bevacizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × spartalizumab × Thoracic × Clear all
NCT03058289 2025-02-27

IT-01

Intensity Therapeutics, Inc.

Phase 1/2 Completed
111 enrolled 21 charts
BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔